2篇
您的检索式：作者名="Daniel G.Stover"
|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Molecular subtyping and genomic profiling expand precision medicine in refractory metastatic triple-negative breast cancer:the FUTURE trial显示文摘Triple-negative breast cancer(TNBC)is a highly heterogeneous disease,and molecular subtyping may result in improved diagnostic precision and targeted therapies.Our previous study classified TNBCs into four subtypes with putative therapeutic targets.Here,we conducted the FUTURE trial(ClinicalTrials.gov identifer:NCT03805399),a phaseⅠb/Ⅱsubtyping-based and genomic biomarker-guided umbrella trial,to evaluate the efficacy of these targets.Patients with refractory metastatic TNBC were enrolled and stratifed by TNBC subtypes and genomic biomarkers,and assigned to one of these seven arms:(A)pyrotinib with capecitabine,(B)androgen receptor inhibitor with CDK4/6 inhibitor,(C)anti PD-1 with nab-paclitaxel,(D)PARP inhibitor included,(E)and(F)anti-VEGFR included,or(G)mTOR inhibitor with nab paclitaxel.The primary end point was the objective response rate(ORR).We enrolled 69 refractory metastatic TNBC patients with a median of three previous lines of therapy(range,1-8).Objective response was achieved in 20(29.0%,95%confidence interval(CI):18.7%-41.2%)of the 69 intention-to-treat(ITT)patients.Our results showed that immunotherapy(arm C),in particular,achieved the highest ORR(52.6%,95%CI:28.9%-75.6%)in the ITT population.Arm E demonstrated favorable ORR(26.1%,95%C:10.2%-48.4%in the ITT population)but with more high grade(23)adverse events.Somatic mutations of TOP2A and CD8 immunohistochemical score may have the potential to predict immunotherapy response in the immunomodulatory subtype of TNBC.In conclusion,the phaseⅠb/ⅡFUTURE trial suggested a new concept for TNBC treatment,demonstrating the clinical beneft of subtyping-based targeted therapy for refractory metastatic TNBC. | Yi-Zhou Jiang Yin Liu Yi Xiao Xin Hu Lin Jiang Wen-ia Zuo Ding Ma Jiahan Ding Xiaoyu Zhu Jianjun Zou Claire Verschraegen Daniel G.Stover Virginia Kaklamani Zhong-Hua Wang Zhi-Ming Shao | 2021 | Cell Research2021，31，2： | 37 |
| 2 | 三阴性乳腺癌基因组与转录组全景图:亚型及治疗策略显示文摘文章简介三阴性乳腺癌(triple-negative breast cancer,TNBC)是雌激素受体、孕激素受体和HER-2均为阴性的一群乳腺癌,缺乏有效靶向治疗,预后差,是乳腺癌学界的世界性难题。近年的研究表明TNBC是一个异质性很强的群体,为更全面而深入地认识这类疾病,寻找精准治疗的突破口,研究团队全面分析了465例原发性三阴性乳腺癌(TNBC)队列的临床、基因组学和转录组学数据。 | Yi-Zhou Jiang Ding Ma Chen Suo Jinxiu Shi Mengzhu Xue Xin Hu Yi Xiao Ke-Da Yu Yi-Rong Liu Ying Yu Yuanting Zheng Xiangnan Li Chenhui Zhang Pengchen Hu Jing Zhang Qi Hua Jiyang Zhang Wanwan Hou Luyao Ren Ding Bao Bingying Li Jingcheng Yang Ling Yao Wen-Jia Zuo Shen Zhao Yue Gong Yi-Xing Ren Ya-Xin Zhao Yun-Song Yang Zhenmin Niu Zhi-Gang Cao Daniel G.Stover Claire Verschraegen Virginia Kaklamani Anneleen Daemen John R.Benson Kazuaki Takabe Fan Bai Da-Qiang Li 王鹏 石乐明 黄薇 邵志敏 | 2020 | 科学新闻2020，，2： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员